10x Genomics (TXG) Cash from Operations (2018 - 2026)

10x Genomics (TXG) has 9 years of Cash from Operations data on file, last reported at 26120000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 23.96% year-over-year to 26120000.0; the trailing twelve-month figure through Mar 2026 stood at 127819000.0 (up 125.27% YoY), and the FY2025 full-year result was 136050000.0, up 1941.57% from the prior year.
• Cash from Operations eased to 26120000.0 in Q1 2026, from 40777000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 43214000.0 in Q3 2025 to a low of 25304000.0 in Q3 2023.
• A 5-year average of 7060647.06 and a median of 7496000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 643.69% in 2022 and soared 704.28% in 2025, its largest moves.
• Tracing TXG's Cash from Operations over 5 years: stood at 13723000.0 in 2022, then jumped by 87.7% to 25758000.0 in 2023, then slumped by 126.2% to 6748000.0 in 2024, then soared by 704.28% to 40777000.0 in 2025, then plunged by 35.94% to 26120000.0 in 2026.
• Business Quant data shows TXG's Cash from Operations at 26120000.0 in Q1 2026, 40777000.0 in Q4 2025, and 43214000.0 in Q3 2025.